Cargando…
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
KRAS mutations drive resistance to targeted therapies, including EGFR inhibitors in colorectal cancer (CRC). Through genetic screens, we unexpectedly find that mutant HRAS, which is rarely found in CRC, is a stronger driver of resistance than mutant KRAS. This difference is ascribed to common codon...
Autores principales: | Ali, Moiez, Kaltenbrun, Erin, Anderson, Gray R., Stephens, Sarah Jo, Arena, Sabrina, Bardelli, Alberto, Counter, Christopher M., Wood, Kris C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472712/ https://www.ncbi.nlm.nih.gov/pubmed/28593995 http://dx.doi.org/10.1038/ncomms15617 |
Ejemplares similares
-
Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway
por: Peterson, Jackson, et al.
Publicado: (2020) -
Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis
por: Le Roux, Özgün, et al.
Publicado: (2022) -
Reduced HRAS(G12V)-Driven Tumorigenesis of Cell Lines Expressing KRAS(C118S)
por: Huang, Lu, et al.
Publicado: (2015) -
Somatic mutation driven codon transition bias in human cancer
por: Son, Hyeonju, et al.
Publicado: (2017) -
Codon usage bias
por: Parvathy, Sujatha Thankeswaran, et al.
Publicado: (2021)